Home
    • Plans Blog Contact
    Akanda Corp logo

    Akanda Corp

    AKAN
    Last price US$6.29
    Market cap US$25.3m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Akanda Corp Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom. Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Akanda Corp into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jun 18, 2026

    Quarterly result summary

    Exhibit 99.1 Akanda Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement TORONTO, ON, June 18, 2026 — Akanda Corp. (NASDAQ: AKAN) (the “Company” or “Akanda”), today announced that it received a notification letter from the Lis...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 6-K Jun 18, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 12, 2026 Earnings release PRESS RELEASE DATED JUNE 12, 2026 Jun 12, 2026 SEC filing ANNUAL REPORT Jun 09, 2026 Earnings release PRESS RELEASE DATED MAY 22, 2026, REGARDING COMPANY SPECIAL MEETING May 22, 2026 Earnings release PRESS RELEASE DATED MAY 22, 2026, REGARDING NASDAQ LISTING May 22, 2026 SEC filing CURRENT REPORT May 22, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Apr 29, 2026 SEC filing AKANDA ADJOURNS SHAREHOLDER MEETING Apr 29, 2026 Earnings release PRESS RELEASE, DATED APRIL 9, 2026, ANNOUNCING SHARE CONSOLIDATION Apr 09, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Apr 09, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 1.00/5
    Akanda Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Akanda Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Akanda Corp AKAN US$25.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Akanda Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Akanda Corp AKAN US$25.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 2.41/5
    Akanda Corp registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Akanda Corp AKAN US$25.3m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Akanda Corp logo

    Akanda Corp

    US$6.29

    US$25.3m

    -28.34%

    N/A